Aurinia reports last patient study visit in Aurora phase 3 lupus nephritis study
Aurinia Pharmaceuticals reported that the last patient study visit has occurred in the AURORA Phase 3 lupus nephritis study. Efficacy and safety results from AURORA remain on track to be reported by the end of the fourth quarter 2019. October 16, 2019